FAS promoter polymorphisms and cancer risk: A meta-analysis based on 34 case-control studies

Carcinogenesis

Volumn 30, Issue 3, 2009, Pages 487-493

  Zhang, Zhizhong ^a   Xue, Hengchuan ^b   Gong, Weida ^c   Wang, Meilin ^a   Yuan, Lin ^a   Han, Suping ^a   Zhang, Zhengdong ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b Yangzhong People's Hospital   (China)

^c YIXING PEOPLE S HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE; FAS ANTIGEN; GUANINE;

ARTICLE; BREAST CANCER; CANCER RISK; CARCINOGENESIS; CASE CONTROL STUDY; ESOPHAGUS CANCER; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HUMAN; LUNG CANCER; MELANOMA; NUCLEIC ACID BASE SUBSTITUTION; PENETRANCE; PRIORITY JOURNAL; PROMOTER REGION; RISK FACTOR; SMOKING HABIT; STOMACH CANCER; UTERINE CERVIX CANCER;

ANTIGENS, CD95; CASE-CONTROL STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; NEOPLASMS; POLYMORPHISM, GENETIC; PROMOTER REGIONS, GENETIC; SMOKING;

EID: 62349111799     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgp016     Document Type: Article

References (55)

1. Zornig,M. et al. (2001) Apoptosis regulators and their role in tumorigenesis. Biochim. Biophys. Acta, 1551, F1-F37.
2. Thompson,C.B. (1995) Apoptosis in the pathogenesis and treatment of disease. Science, 267, 1456-1462.
3. Evan,G.I. et al. (2001) Proliferation, cell cycle and apoptosis in cancer. Nature, 411, 342-348.
4. Krammer,P.H. et al. (1994) Regulation of apoptosis in the immune system. Curr. Opin. Immunol., 6, 279-289.
5. Itoh,N. et al. (1991) The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell, 66 233-243.
6. Oehm,A. et al. (1992) Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily. Sequence identity with the Fas antigen. J. Biol. Chem., 267, 10709-10715.
7. Houston,A. et al. (2004) The Fas signalling pathway and its role in the pathogenesis of cancer. Curr. Opin. Pharmacol., 4, 321-326.
8. Lee,S.H. et al. (1999) Transitional cell carcinoma expresses high levels of Fas ligand in vivo. BJU Int., 83, 698-702.
9. Mizutani,Y. et al. (2001) Significance of serum soluble Fas ligand in patients with bladder carcinoma. Cancer, 92, 287-293.
10. Huang,Q.R. et al. (1997) Identification and characterization of polymorphisms in the promoter region of the human Apo-1/Fas (CD95) gene. Mol. Immunol., 34, 577-582.
11. Koshkina,N.V. et al. (2007) Exploratory analysis of Fas gene polymorphisms in pediatric osteosarcoma patients. J. Pediatr. Hematol. Oncol., 29, 815-821.
12. Ho,T. et al. (2008) Fas single nucleotide polymorphisms and risk of thyroid and salivary gland carcinomas: A case-control analysis. Head Neck, 30, 297-305.
13. Sibley,K. et al. (2003) Functional FAS promoter polymorphisms are associated with increased risk of acute myeloid leukemia. Cancer Res. 63, 4327-4330.
14. Nelson,H.H. et al. (2001) Fas/APO-1 promoter polymorphism is not associated with non-melanoma skin cancer. Cancer Epidemiol. Biomarkers Prev., 10, 809-810.
15. Lai,H.C. et al. (2003) Single nucleotide polymorphism at Fas promoter is associated with cervical carcinogenesis. Int. J. Cancer 103, 221-225.
16. Wang,L.E. et al. (2003) Fas A670G polymorphism, apoptotic capacity in lymphocyte cultures, and risk of lung cancer. Lung Cancer, 42, 1-8.
17. Dybikowska,A. et al. (2004) Evaluation of Fas gene promoter polymorphism in cervical cancer patients. Int. J. Mol. Med., 14 475-478.
18. Krippl,P. et al. (2004) Re: Polymorphisms of death pathway genes FAS and FASL in esophageal squamous-cell carcinoma. J. Natl Cancer Inst., 96, 1478-1479; author reply 1479.
19. Sun,T. et al. (2004) Polymorphisms of death pathway genes FAS and FASL in esophageal squamous-cell carcinoma. J. Natl Cancer Inst., 96, 1030-1036.
20. Lai,H.C. et al. (2005) Genetic polymorphisms of FAS and FASL (CD95/CD95L) genes in cervical carcinogenesis: An analysis of haplotype and gene-gene interaction. Gynecol. Oncol., 99, 113-118.
21. Sun,T. et al. (2005) FASL-844C polymorphism is associated with increased activation-induced T cell death and risk of cervical cancer. J. Exp. Med., 202, 967-974.
22. Ueda,M. et al. (2005) Fas gene promoter-670 polymorphism (A/G) is associated with cervical carcinogenesis. Gynecol. Oncol., 98 129-133.
23. Zhang,X. et al. (2005) Functional polymorphisms in cell death pathway genes FAS and FASL contribute to risk of lung cancer. J. Med. Genet., 42, 479-484.
24. Zoodsma,M. et al. (2005) Interleukin-10 and Fas polymorphisms and susceptibility for (pre)neoplastic cervical disease. Int. J. Gynecol. Cancer, 15 (suppl. 3), 282-290.
25. Bel Hadj Jrad,B. (2006) A polymorphism in FAS gene promoter associated with increased risk of nasopharyngeal carcinoma and correlated with antinuclear autoantibodies induction. Cancer Lett., 233, 21-27.
26. Ikehara,S.K. et al. (2006) A polymorphism of C-to-T substitution at -31 IL1B is associated with the risk of advanced gastric adenocarcinoma in a Japanese population. J. Hum. Genet., 51, 927-933.
27. Li,C. et al. (2006) Polymorphisms of the FAS and FAS ligand genes associated with risk of cutaneous malignant melanoma. Pharmacogenet. Genomics, 16, 253-263.
28. Li,C. et al. (2006) Functional polymorphisms in the promoter regions of the FAS and FAS ligand genes and risk of bladder cancer in south China: A case-control analysis. Pharmacogenet. Genomics, 16, 245-251.
29. Park,S.H. et al. (2006) Polymorphisms in the FAS and FASL genes and risk of lung cancer in a Korean population. Lung Cancer, 54 303-308.
30. Ueda,M. et al. (2006) Fas gene promoter -670 polymorphism in gynecological cancer. Int. J. Gynecol. Cancer, 16 (suppl. 1), 179-182.
31. Zhang,Z. et al. (2006) Polymorphisms of FAS and FAS ligand genes involved in the death pathway and risk and progression of squamous cell carcinoma of the head and neck. Clin. Cancer Res., 12, 5596-5602.
32. Crew,K.D. et al. (2007) Genetic polymorphisms in the apoptosis-associated genes FAS and FASL and breast cancer risk. Carcinogenesis, 28, 2548-2551.
33. Erdogan,M. et al. (2007) Fas/Fas ligand gene polymorphism in patients with papillary thyroid cancer in the Turkish population. J. Endocrinol. Invest., 30, 411-416.
34. Gormus,U. et al. (2007) Fas-1377 A/G polymorphism in lung cancer. In Vivo, 21, 663-666.
35. Gormus,U. et al.. (2007) Fas-1377A/G and FasL-844 T/C gene polymorphisms and epithelial ovarian cancer. Anticancer Res., 27, 991-994.
36. Jain,M. et al. (2007) Role of BCL2 (ala43thr), CCND1 (G870A) and FAS (A-670G) polymorphisms in modulating the risk of developing esophageal cancer. Cancer Detect. Prev., 31, 225-232.
37. Zhang,B. et al. (2007) Functional polymorphisms in FAS and FASL contribute to increased apoptosis of tumor infiltration lymphocytes and risk of breast cancer. Carcinogenesis, 28, 1067-1073.
38. Zhang,H. et al. (2007) Importance of FAS-1377, FAS-670, and FASL-844 polymorphisms in tumor onset, progression, and pigment phenotypes of Swedish patients with melanoma: A case-control analysis. Cancer J., 13, 233-237.
39. Farre,L. et al. (2008) Fas 670 promoter polymorphism is associated to susceptibility, clinical presentation, and survival in adult T cell leukemia. J. Leukoc. Biol., 83, 220-222.
40. Hsu,P.I. et al. (2008) Polymorphisms of death pathway genes FAS and FASL and risk of premalignant gastric lesions. Anticancer Res. 28, 97-103.
41. Kang,S. et al. (2008) FAS-1377 G/A polymorphism and the risk of lymph node metastasis in cervical cancer. Cancer Genet. Cytogenet. 180, 1-5.
42. Lima,L. et al.. (2008) Association between FAS polymorphism and prostate cancer development. Prostate Cancer Prostatic Dis., 11 94-98.
43. Tamandani,D.M. et al.. (2008) Association of Fas-670 gene polymorphism with risk of cervical cancer in North Indian population. Clin. Exp. Obstet. Gynecol., 35, 183-186.
44. Ter-Minassian,M. et al. (2008) Apoptosis gene polymorphisms, age, smoking and the risk of non-small cell lung cancer. Carcinogenesis 29, 2147-2152.
45. Yang,M. et al. (2008) Functional variants in cell death pathway genes and risk of pancreatic cancer. Clin. Cancer Res., 14, 3230-3236.
46. Mantel,N. et al. (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J. Natl Cancer Inst., 22, 719-748.
47. DerSimonian,R. et al. (1986) Meta-analysis in clinical trials. Control. Clin. Trials, 7, 177-188.
48. Whitehead,A. et al. (1991) A general parametric approach to the meta-analysis of randomized clinical trials. Stat. Med., 10, 1665-1677.
49. Egger,M. et al. (1997) Bias in meta-analysis detected by a simple, graphical test. Br. Med. J., 315, 629-634.
50. Hirschhorn,J.N. et al. (2002) A comprehensive review of genetic association studies. Genet. Med., 4, 45-61.
51. Cohen,S.M. et al. (2000) Epidemiology and etiology of premalignant and malignant urothelial changes. Scand. J. Urol. Nephrol., (Suppl. 34), 105-115.
52. Qiu,D. et al. (2005) Overview of the epidemiology of pancreatic cancer focusing on the JACC Study. J. Epidemiol., 15 (suppl. 2), S157-S167.
53. Wei,Q. et al.. (2000) Repair of tobacco carcinogen-induced DNA adducts and lung cancer risk: A molecular epidemiologic study. J. Natl Cancer Inst., 92, 1764-1772.
54. Zeidel,A. et al. (2002) Immune response in asymptomatic smokers. Acta Anaesthesiol. Scand., 46, 959-964.
55. Elnemr,A. et al. (2001) Human pancreatic cancer cells express non-functional Fas receptors and counterattack lymphocytes by expressing Fas ligand; a potential mechanism for immune escape. Int. J. Oncol. 18, 33-39.